Sanofi Pasteur: The Dengue Vaccine Dilemma Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for Sanofi Pasteur: The Dengue Vaccine Dilemma case study

At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. Sanofi Pasteur: The Dengue Vaccine Dilemma case study is a Harvard Business School (HBR) case study written by V. Kasturi Rangan, David E. Bloom, Vincent Dessain, Emilie Billaud. The Sanofi Pasteur: The Dengue Vaccine Dilemma (referred as “Vaccine Pasteur” from here on) case study provides evaluation & decision scenario in field of Global Business. It also touches upon business topics such as - Value proposition, Health, Marketing, Product development, Social enterprise.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment

---

Case Description of Sanofi Pasteur: The Dengue Vaccine Dilemma Case Study

In 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a good balanced immune answer, it had a proof of efficacy of only 30%, far below the 70% mark the company had targeted. Guillaume Leroy, vice president of the Dengue Company at Sanofi Pasteur, reflected on the Phase IIb trial's surprising outcome and the way forward. He had to decide whether to go ahead with the vaccine trials and production, and if so, needed to develop a strategic plan on how to price and deliver the vaccine for a rapid roll-out.

Case Authors : V. Kasturi Rangan, David E. Bloom, Vincent Dessain, Emilie Billaud

Topic : Global Business

Related Areas : Health, Marketing, Product development, Social enterprise

---

Calculating Net Present Value (NPV) at 6% for Sanofi Pasteur: The Dengue Vaccine Dilemma Case Study

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 6 %	Discounted Cash Flows
Year 0	(10018680)	-10018680	-	-
Year 1	3453782	-6564898	3453782	0.9434	3258285
Year 2	3960270	-2604628	7414052	0.89	3524626
Year 3	3967091	1362463	11381143	0.8396	3330846
Year 4	3227069	4589532	14608212	0.7921	2556141
TOTAL			14608212		12669898

The Net Present Value at 6% discount rate is 2651218

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting

What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.

---

Capital Budgeting Approaches

Methods of Capital Budgeting

There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Profitability Index
2. Payback Period
3. Net Present Value
4. Internal Rate of Return

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Vaccine Pasteur shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.
2. Timing of the expected cash flows – stockholders of Vaccine Pasteur have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.

---

Formula and Steps to Calculate Net Present Value (NPV) of Sanofi Pasteur: The Dengue Vaccine Dilemma

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Global Business Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Vaccine Pasteur often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Vaccine Pasteur needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 15 %	Discounted Cash Flows
Year 0	(10018680)	-10018680	-	-
Year 1	3453782	-6564898	3453782	0.8696	3003289
Year 2	3960270	-2604628	7414052	0.7561	2994533
Year 3	3967091	1362463	11381143	0.6575	2608427
Year 4	3227069	4589532	14608212	0.5718	1845087
TOTAL					10451336

The Net NPV after 4 years is 432656

(10451336 - 10018680 )

---

Calculating Net Present Value (NPV) at 20%

If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 20 %	Discounted Cash Flows
Year 0	(10018680)	-10018680	-	-
Year 1	3453782	-6564898	3453782	0.8333	2878152
Year 2	3960270	-2604628	7414052	0.6944	2750188
Year 3	3967091	1362463	11381143	0.5787	2295770
Year 4	3227069	4589532	14608212	0.4823	1556264
TOTAL					9480373

The Net NPV after 4 years is -538307

At 20% discount rate the NPV is negative (9480373 - 10018680 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Vaccine Pasteur to discount cash flow at lower discount rates such as 15%.

Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Vaccine Pasteur has a NPV value higher than Zero then finance managers at Vaccine Pasteur can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Vaccine Pasteur, then the stock price of the Vaccine Pasteur should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Vaccine Pasteur should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What can impact the cash flow of the project.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

Understanding of risks involved in the project.

What will be a multi year spillover effect of various taxation regulations.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.

---

Negotiation Strategy of Sanofi Pasteur: The Dengue Vaccine Dilemma

References & Further Readings

V. Kasturi Rangan, David E. Bloom, Vincent Dessain, Emilie Billaud (2018), "Sanofi Pasteur: The Dengue Vaccine Dilemma Harvard Business Review Case Study. Published by HBR Publications.